Latest Breaking News On - Founder of ampio pharmaceuticals - Page 1 : comparemela.com

Share this article Share this article ENGLEWOOD, Colo., April 19, 2021 /PRNewswire/  Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced findings of pre-clinical research demonstrating that Ampio s lead drug candidate, Ampion™, provides some of the same anti-inflammatory effects as the steroid dexamethasone but without the significant adverse events associated with steroids. Steroids such as dexamethasone are globally immunosuppressive, to both innate and adaptive immune systems, with effects that are beneficial in the short term and often harmful long-term, said David Bar-Or, M.D., Director and Founder of Ampio Pharmaceuticals.

United statesKatie kennedySimilaritiesbetween ampionJoe hassettMichael macalusoExchange commissionFounder of ampio pharmaceuticalsAmpio pharmaceuticalsCompany contactsAmpio pharmaceuticals incDavid bar orIngenuity pathway analysisPrivate securities litigation reform actBiological license applicationAnnual reportHealth care amp hospitals